Non-small-cell lung cancer patients harboring TP53/KRAS co-mutation could benefit from a PD-L1 inhibitor Supplementary Figure 1

This study was supported jointly by Special Funds for Taishan Scholars Project (grant no. tsqn201812149) and the Academic Promotion Program of Shandong First Medical University (2019RC004). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.